GLP-1 medications for adults with heart failure

Adults with heart failure can use GLP-1 medications like semaglutide and tirzepatide to treat obesity and cardiometabolic risk, but the monitoring plan looks different than it does for a patient without heart disease. A failing heart changes how nausea, dehydration, and a sudden shift on the scale should be read, so dosing and follow-up need a clinician who is tracking cardiac status alongside weight, not just weight.

TL;DR

• Semaglutide (Wegovy) improved heart failure symptoms in the 2023 STEP-HFpEF trial, not just body weight.
• Tirzepatide (Zepbound) produces the largest average weight loss among GLP-1 medications for heart failure patients.
• GoodLife Health's Biomarker Audit checks ApoB, hs-CRP, and kidney function before and during GLP-1 therapy.
• Never start a GLP-1 for heart failure without your cardiologist reviewing your diuretic dose first.
• Compounded GLP-1s are never used at GoodLife Health because heart failure patients need monitored, branded dosing.

Why this matters

Obesity is one of the strongest modifiable drivers of heart failure with preserved ejection fraction, known as HFpEF, and it worsens symptoms in heart failure with reduced ejection fraction too. GoodLife Health treats weight, blood pressure, lipids, and heart failure risk as one interconnected system rather than separate problems handled by separate specialists, which is the entire premise of GoodLife Health and its Cardiometabolic Optimization Membership.

The evidence for GLP-1 therapy in heart failure stopped being theoretical in 2023. The STEP-HFpEF trial put semaglutide against placebo in patients with HFpEF and obesity, and the semaglutide group lost 13.3% of body weight on average against 2.6% on placebo, while symptom scores on the Kansas City Cardiomyopathy Questionnaire improved by 16.6 points against 8.7 on placebo. That is a heart failure outcome, not a cosmetic one — patients could walk farther and breathe easier, not just weigh less.

Tirzepatide has its own heart failure data. The SUMMIT trial tested tirzepatide specifically in HFpEF patients with obesity and found it reduced the risk of worsening heart failure events and improved symptoms and physical function. Neither trial makes GLP-1 therapy a substitute for guideline-directed heart failure medications — beta-blockers, ACE inhibitors or ARNIs, SGLT2 inhibitors, and mineralocorticoid receptor antagonists still do the heavy lifting. A GLP-1 sits on top of that regimen, not in place of it.

How to approach GLP-1 therapy when you have heart failure

Confirm your heart failure type and current status first

Ejection fraction and volume status change what a clinician watches for on a GLP-1. HFpEF, HFrEF, and HFmrEF respond differently to weight loss and fluid shifts, so this step comes before any prescribing conversation.

• Pull your most recent echocardiogram and ejection fraction number
• Know your NYHA functional class (I through IV)
• Ask whether you are currently euvolemic or holding fluid
• Get your most recent BNP or NT-proBNP result
• Note your last heart failure hospitalization date, if any

Map your heart failure medications against GLP-1 interactions

Most heart failure regimens include a diuretic, and GLP-1 medications cause nausea, vomiting, or reduced appetite in a meaningful share of patients during titration. Stack those two effects and dehydration risk climbs fast in someone already managing fluid balance.

• List every diuretic, ACE inhibitor/ARB or ARNI, beta-blocker, SGLT2 inhibitor, and MRA you take
• Flag any drug that already lowers blood pressure or blurs fluid status (SGLT2 inhibitors do both)
• Check for potassium-sparing drugs like spironolactone that need electrolyte tracking
• Bring this list to the same clinician managing your GLP-1 dose, not a separate telehealth app

Get baseline cardiometabolic labs before the first dose

This is where a comprehensive lab panel earns its place — not as an upsell, but as the only way to know if a GLP-1 is moving the numbers that actually predict heart failure progression. GoodLife Health's Biomarker Audit runs every 90 days as part of the Cardiometabolic Optimization Membership and covers the panel below alongside kidney function and electrolytes, which heart failure patients need tracked more closely than a general weight-loss patient.

• ApoB and Lp(a) for cardiovascular risk beyond a standard lipid panel
• hs-CRP for inflammation
• HbA1c and fasting insulin markers for metabolic status
• Full thyroid panel, since thyroid dysfunction mimics and worsens heart failure symptoms
• Basic metabolic panel for kidney function and potassium, given diuretic and MRA use

!Five-step timeline for starting a GLP-1 with heart failure

Labs and medication review come before the prescription, not after.

Choose the GLP-1 that matches your cardiac and metabolic profile

Not every GLP-1 has heart failure outcome data behind it, and that distinction matters more here than in a general weight-loss decision. GoodLife Health prescribes branded, FDA-approved GLP-1 medications only — Wegovy, Zepbound, Ozempic, Mounjaro, and the oral options Wegovy Tablets and Foundayo — and never compounded semaglutide or tirzepatide, which carry no equivalent monitoring or dosing consistency.

• Semaglutide (Wegovy): the medication behind the STEP-HFpEF symptom data, average 13.3% weight loss in that trial and roughly 15% average in the broader STEP-1 program
• Tirzepatide (Zepbound): the medication behind the SUMMIT HFpEF outcome data, with average weight loss up to roughly 22.5% in the SURMOUNT-1 trial population
• Semaglutide (Ozempic) or tirzepatide (Mounjaro): the same molecules dosed for type 2 diabetes, relevant if insurance coverage is tied to a diabetes diagnosis rather than obesity
• Oral GLP-1 (Wegovy Tablets, Foundayo/orforglipron): an option for patients who want to avoid injections, with its own fasting and administration rules
• Individual results vary, and none of these figures are a promise — they describe trial populations, not any one patient

Manage fluid status and hydration through dose titration

GI side effects that a healthy 35-year-old shrugs off can push a heart failure patient toward dehydration or an electrolyte problem within days. This is the step where heart failure changes the standard GLP-1 playbook the most.

• Weigh yourself daily at the same time and track the trend, not the single number
• Report any 3-5 lb weight change in 24-48 hours immediately — that is fluid, not fat
• Increase water intake gradually during nausea or reduced appetite, especially on diuretic days
• Ask your clinician whether your diuretic dose needs a temporary adjustment during titration
• Watch for dizziness or lightheadedness, which can signal both dehydration and over-diuresis

!A scale, a glass of water, and a weight-tracking notebook

Daily weigh-ins catch fluid shifts before they become a hospital visit.

Track the numbers that actually predict heart failure progress

Weight loss alone tells an incomplete story in this population. Symptom scores and repeat labs tell the clinician whether the GLP-1 is doing what the trials showed it can do.

• Repeat NT-proBNP at intervals your clinician sets, not on a fixed weight-loss schedule
• Track NYHA functional class changes — can you walk farther without stopping
• Re-check ApoB, hs-CRP, and HbA1c at each 90-day Biomarker Audit
• Log symptom changes (breathlessness, swelling, exercise tolerance) alongside weight

Coordinate between your cardiologist and your weight-loss clinician

A GLP-1 prescribed in isolation from cardiology creates blind spots. Heart failure medication changes and GLP-1 titration need to happen on the same page, literally.

• Send GLP-1 dosing updates to your cardiologist at each titration step
• Ask your cardiologist to flag any planned diuretic or MRA dose change before you start a new GLP-1 dose
• Confirm your clinician has your most recent echocardiogram and hospitalization history on file
• Under GoodLife Health's clinical protocols, physicians licensed in all 50 states run this coordination as part of the membership rather than leaving it to the patient to relay notes between offices

Know the red-flag symptoms that mean stop and call

Some symptoms during GLP-1 therapy need same-day contact with a clinician, not a wait-and-see approach, when heart failure is in the picture.

• Sudden weight gain of more than 3-5 lbs in a week (fluid retention, not fat gain)
• Worsening shortness of breath, especially lying flat (orthopnea)
• New swelling in the legs, ankles, or abdomen
• Fainting, severe dizziness, or a racing or irregular heartbeat
• Signs of severe dehydration: dark urine, confusion, inability to keep fluids down

Comparing GLP-1 options for heart failure patients

Verdict: semaglutide (Wegovy) is the GLP-1 with the most heart failure symptom data behind it as of 2026, and tirzepatide (Zepbound) is the GLP-1 with the strongest average weight-loss numbers plus emerging HFpEF outcome data — the right pick depends on which trial population and mechanism your clinician thinks fits your cardiac profile.

Common mistakes heart failure patients make on GLP-1 therapy

• Adjusting or stopping their diuretic on their own because GLP-1 nausea makes urination feel inconvenient, which flips fluid balance the wrong direction
• Reading every scale change as fat loss instead of distinguishing the fluid shifts that are normal in heart failure from actual weight loss
• Choosing a compounded GLP-1 from a med spa to save money, without realizing dosing inconsistency is a bigger risk in a heart failure patient than in a healthy one
• Skipping potassium and kidney monitoring while combining a GLP-1 with a mineralocorticoid receptor antagonist like spironolactone
• Assuming the GLP-1 replaces their heart failure medications rather than layering on top of beta-blockers, ARNIs, SGLT2 inhibitors, and MRAs

FAQ

Can people with heart failure take GLP-1 medications like Wegovy or Zepbound?

Yes, GLP-1 medications are used in heart failure patients with obesity, most often when a clinician coordinates dosing with existing heart failure medications and monitors fluid status. The STEP-HFpEF trial specifically studied semaglutide in HFpEF patients with obesity and found symptom improvement, not just weight loss.

Does semaglutide actually help heart failure symptoms, or just weight?

Both. In the 2023 STEP-HFpEF trial, semaglutide improved Kansas City Cardiomyopathy Questionnaire symptom scores by 16.6 points versus 8.7 on placebo, alongside 13.3% average weight loss versus 2.6% on placebo.

Is tirzepatide safe for heart failure with preserved ejection fraction?

Tirzepatide was studied specifically in HFpEF patients with obesity in the SUMMIT trial, which found it reduced the risk of worsening heart failure events. Safety in any individual patient depends on current medications, kidney function, and fluid status reviewed by a clinician.

What heart failure medications interact with GLP-1 drugs?

Diuretics, SGLT2 inhibitors, ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists all interact with GLP-1 side effects, mainly through fluid and electrolyte shifts, not direct drug-drug interactions. A clinician managing both regimens together, rather than two separate providers, catches these overlaps earlier.

Why do GLP-1 side effects matter more for heart failure patients?

Nausea, vomiting, or reduced appetite from a GLP-1 can cause dehydration that compounds with diuretic use in heart failure patients, shifting fluid balance faster than in someone without heart disease. That is why daily weight tracking and hydration monitoring get more attention in this population.

Is compounded semaglutide safe for someone with heart failure?

GoodLife Health does not prescribe compounded semaglutide or tirzepatide under any circumstance, and heart failure patients specifically need the dosing consistency and lab monitoring that come with branded, FDA-approved medications. Compounded versions carry no equivalent quality or dosing oversight.

How often should heart failure patients get lab work while on a GLP-1?

GoodLife Health runs a comprehensive Biomarker Audit every 90 days as part of its Cardiometabolic Optimization Membership, covering ApoB, hs-CRP, HbA1c, and kidney function. Heart failure patients on diuretics or MRAs may need electrolyte checks between those quarterly panels depending on symptoms.

Can a direct primary care membership manage GLP-1 therapy for heart failure patients?

Yes, when the membership includes physicians who review cardiac history, coordinate with cardiology, and run quarterly labs rather than a one-time prescription. GoodLife Health structures its Cardiometabolic Optimization Membership around exactly that kind of ongoing coordination.

One last thing

The number that gets missed most in this conversation is 16.6 — the point gain in heart failure symptom scores from the STEP-HFpEF trial, not the 13.3% weight loss headline. A heart failure patient on a GLP-1 who is breathing easier and walking farther is the actual clinical win in 2026, and the scale is a secondary signal, not the main one. Anyone managing heart failure and considering a GLP-1 should ask their clinician to track symptom scores and NT-proBNP alongside weight, not weight alone.

Related guides

• ApoB lab test: what the number means for heart risk
• Lipid panel explained: what each number means for your heart
• Medical weight loss for men with metabolic syndrome
• GLP-1 and cardiovascular risk: what the studies show

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/